Back to search results

Study of AM3101 for Meniscus Tear Healing

This study is testing a drug called AM3101 to see if it can help meniscus tears heal better and reduce problems after surgery. You might be able to join if you are between 18 and 40 years old, have an MRI showing a meniscus tear (with or without an ACL tear), and meet other health requirements like a healthy BMI and normal liver and kidney function. Researchers will compare AM3101 to a saline placebo (an inactive substance) to see if AM3101 improves healing, as seen on an MRI after 12 months. They will also track any side effects. The study is currently recruiting participants.

Study design
This is a prospective, randomized, controlled, double-blinded study, meaning participants are randomly assigned to receive either AM3101 or a placebo, and neither you nor your doctor will know which you are receiving. It plans to enroll 74 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your meniscus healing and any side effects will be checked for 12 months after the injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05560477

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

Recruiting
PHASE1Ages 18–40InterventionalTreatment
University of Cincinnati
~74 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:AM3101Saline Placebo

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Healing Assessed via MRI
Measured over 12 months
+1 more outcome measured

Conditions

Meniscus Tear

Explore related trials

Finding of tear meniscus

NCT05560477

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Oregon Health & Science University

    Portland, Oregonstudy coordinator listed

    Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohiostudy coordinator listed

    Recruiting

  • University of Cincinnati

    Cincinnati, Ohiostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Brian M Grawe, MD · PRINCIPAL_INVESTIGATOR · University of Cincinnati

Who to contact

Kimberly A Hasselfeld, MS
[email protected]
513-558-1933
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Healing Assessed via MRI12 months

    Presence or absence of healing assessed via MRI

  • Incidence of Adverse Events12 months

    Incidence of adverse events in subjects receiving AM3101 following meniscal repair, as compared to subjects undergoing meniscal repair and injected with a saline solution (placebo).